Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26202202 | 0.85 | ATM (0.47) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL3430654 | 0.84 | HCAR2 (0.44) | KDM4EMAPK1L3MBTL1ALDH1A1CA1 | |
| SCHEMBL10088650 | 0.83 | ATM (0.46) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL24214238 | 0.82 | ATM (0.45) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL24214237 | 0.82 | ATM (0.45) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL34470503 | 0.82 | KDM4E (0.53) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL34470376 | 0.82 | MAPT (0.47) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL72042 | 0.82 | KDM4E (0.53) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL335203 | 0.81 | ATM (0.55) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL1063745 | 0.81 | MAPK1 (0.46) | ATMKDM4EMAPK1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282786-A1 | Tricyclic TLR7 Agonists and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-11 | — | — | US | disclosed |
| US-20230118688-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-20 | — | — | US | disclosed |
| EP-4097102-A1 | 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115210236-A | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists | 百时美施贵宝公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2021154661-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-05 | — | — | WO | disclosed |
| US-10189810-B2 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | VERSEON CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189810-B2 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | VERSEON CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-21 | — | — | US | disclosed |
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-21 | — | — | US | disclosed |
| EP-3194369-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | Verseon Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044662-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON CORPORATION (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044662-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON CORPORATION (US) | 2016-03-24 | — | — | WO | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SERPINE1, PRSS1, SPINT2 | ATM 392/4885KDM4E 1769/4885MAPK1 1064/4885 |
| US-20250282786-A1 | Tricyclic TLR7 Agonists and Uses Thereof | TLR7, TLR9, TLR1 | ATM 975/4885KDM4E 3303/4885MAPK1 586/4885 |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | ATM 3418/4885KDM4E 2943/4885MAPK1 4046/4885 |
| US-10189810-B2 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | SERPINE1, PRSS1, SPINT2 | ATM 392/4885KDM4E 1769/4885MAPK1 1064/4885 |
| US-20230118688-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR1, TLR9 | ATM 282/4885KDM4E 2165/4885MAPK1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.